Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2

Yoshiaki Iwasaki, Hironori Tanaka, Hiroshi Ikeada, Ryo Ichi Okamoto, Yasuyuki Araki, Kazuhisa Yabushita, Haruhiko Kobashi, Kazuya Kariyama, Mitsuhiko Kawaguchi, Kouichi Takaguchi, Tatsuro Sakata, Masaharu Ando, Kohsaku Sakaguchi, Noriaki Aoki, Yasushi Shiratori

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective. Several treatment strategies for patients with chronic hepatitis C have been compared mainly in terms of their efficacy, and it has been found that pegylated interferon (IFN) plus ribavirin has become the standard therapy, but aged patients may not tolerate ribavirin and the cost-effectiveness of treatment should also be further considered. We conducted a study to evaluate the efficacy, safety, and cost-effectiveness of consensus IFN monotherapy with high-dose induction for patients with chronic hepatitis C in clinical practice. Material and Methods. We consecutively enrolled 104 patients with chronic hepatitis C. Patients were scheduled to receive 12 or 18 μg of consensus IFN daily for 2 weeks, then three times a week for 22 weeks. Efficacy, safety, and cost-effectiveness were assessed. A Markov model was developed to investigate cost-effectiveness in patients with chronic hepatitis C treated by different IFN-based treatment strategies. Results. Of the 104 study patients, a sustained virological response (SVR) was achieved in 66 (63%). Logistic regression analysis revealed that genotype 2, lower hepatitis C virus RNA levels, and patient age were independently associated with SVR. The response rate was significantly higher in patients with genotype 2 (51/66, 77%) versus genotype 1 (15/38, 40%). Cost-effectiveness analysis in patients with genotype 2 revealed that high-dose induction with consensus IFN monotherapy was as highly cost-effective as pegylated IFN plus ribavirin. Conclusion. Consensus IFN monotherapy with high-dose induction shows high efficacy and cost-effectiveness in chronic hepatitis C patients with genotype 2 infection. Thus, it may be a reliable alternative in aged patients and for those excluded from standard combination therapy.

Original languageEnglish
Pages (from-to)79-90
Number of pages12
JournalScandinavian Journal of Gastroenterology
Volume46
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Hepatitis C
Interferons
Cost-Benefit Analysis
Genotype
Chronic Hepatitis C
Ribavirin
Therapeutics
Safety
Hepacivirus
Logistic Models
Regression Analysis
RNA
Costs and Cost Analysis

Keywords

  • Chronic hepatitis C
  • Consensus interferon
  • Cost-effectiveness
  • Genotype 2
  • High-dose induction

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2. / Iwasaki, Yoshiaki; Tanaka, Hironori; Ikeada, Hiroshi; Okamoto, Ryo Ichi; Araki, Yasuyuki; Yabushita, Kazuhisa; Kobashi, Haruhiko; Kariyama, Kazuya; Kawaguchi, Mitsuhiko; Takaguchi, Kouichi; Sakata, Tatsuro; Ando, Masaharu; Sakaguchi, Kohsaku; Aoki, Noriaki; Shiratori, Yasushi.

In: Scandinavian Journal of Gastroenterology, Vol. 46, No. 1, 01.2011, p. 79-90.

Research output: Contribution to journalArticle

Iwasaki, Y, Tanaka, H, Ikeada, H, Okamoto, RI, Araki, Y, Yabushita, K, Kobashi, H, Kariyama, K, Kawaguchi, M, Takaguchi, K, Sakata, T, Ando, M, Sakaguchi, K, Aoki, N & Shiratori, Y 2011, 'Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2', Scandinavian Journal of Gastroenterology, vol. 46, no. 1, pp. 79-90. https://doi.org/10.3109/00365521.2010.516449
Iwasaki, Yoshiaki ; Tanaka, Hironori ; Ikeada, Hiroshi ; Okamoto, Ryo Ichi ; Araki, Yasuyuki ; Yabushita, Kazuhisa ; Kobashi, Haruhiko ; Kariyama, Kazuya ; Kawaguchi, Mitsuhiko ; Takaguchi, Kouichi ; Sakata, Tatsuro ; Ando, Masaharu ; Sakaguchi, Kohsaku ; Aoki, Noriaki ; Shiratori, Yasushi. / Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2. In: Scandinavian Journal of Gastroenterology. 2011 ; Vol. 46, No. 1. pp. 79-90.
@article{71a642d0683d4e1e84f69487ca364bae,
title = "Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2",
abstract = "Objective. Several treatment strategies for patients with chronic hepatitis C have been compared mainly in terms of their efficacy, and it has been found that pegylated interferon (IFN) plus ribavirin has become the standard therapy, but aged patients may not tolerate ribavirin and the cost-effectiveness of treatment should also be further considered. We conducted a study to evaluate the efficacy, safety, and cost-effectiveness of consensus IFN monotherapy with high-dose induction for patients with chronic hepatitis C in clinical practice. Material and Methods. We consecutively enrolled 104 patients with chronic hepatitis C. Patients were scheduled to receive 12 or 18 μg of consensus IFN daily for 2 weeks, then three times a week for 22 weeks. Efficacy, safety, and cost-effectiveness were assessed. A Markov model was developed to investigate cost-effectiveness in patients with chronic hepatitis C treated by different IFN-based treatment strategies. Results. Of the 104 study patients, a sustained virological response (SVR) was achieved in 66 (63{\%}). Logistic regression analysis revealed that genotype 2, lower hepatitis C virus RNA levels, and patient age were independently associated with SVR. The response rate was significantly higher in patients with genotype 2 (51/66, 77{\%}) versus genotype 1 (15/38, 40{\%}). Cost-effectiveness analysis in patients with genotype 2 revealed that high-dose induction with consensus IFN monotherapy was as highly cost-effective as pegylated IFN plus ribavirin. Conclusion. Consensus IFN monotherapy with high-dose induction shows high efficacy and cost-effectiveness in chronic hepatitis C patients with genotype 2 infection. Thus, it may be a reliable alternative in aged patients and for those excluded from standard combination therapy.",
keywords = "Chronic hepatitis C, Consensus interferon, Cost-effectiveness, Genotype 2, High-dose induction",
author = "Yoshiaki Iwasaki and Hironori Tanaka and Hiroshi Ikeada and Okamoto, {Ryo Ichi} and Yasuyuki Araki and Kazuhisa Yabushita and Haruhiko Kobashi and Kazuya Kariyama and Mitsuhiko Kawaguchi and Kouichi Takaguchi and Tatsuro Sakata and Masaharu Ando and Kohsaku Sakaguchi and Noriaki Aoki and Yasushi Shiratori",
year = "2011",
month = "1",
doi = "10.3109/00365521.2010.516449",
language = "English",
volume = "46",
pages = "79--90",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2

AU - Iwasaki, Yoshiaki

AU - Tanaka, Hironori

AU - Ikeada, Hiroshi

AU - Okamoto, Ryo Ichi

AU - Araki, Yasuyuki

AU - Yabushita, Kazuhisa

AU - Kobashi, Haruhiko

AU - Kariyama, Kazuya

AU - Kawaguchi, Mitsuhiko

AU - Takaguchi, Kouichi

AU - Sakata, Tatsuro

AU - Ando, Masaharu

AU - Sakaguchi, Kohsaku

AU - Aoki, Noriaki

AU - Shiratori, Yasushi

PY - 2011/1

Y1 - 2011/1

N2 - Objective. Several treatment strategies for patients with chronic hepatitis C have been compared mainly in terms of their efficacy, and it has been found that pegylated interferon (IFN) plus ribavirin has become the standard therapy, but aged patients may not tolerate ribavirin and the cost-effectiveness of treatment should also be further considered. We conducted a study to evaluate the efficacy, safety, and cost-effectiveness of consensus IFN monotherapy with high-dose induction for patients with chronic hepatitis C in clinical practice. Material and Methods. We consecutively enrolled 104 patients with chronic hepatitis C. Patients were scheduled to receive 12 or 18 μg of consensus IFN daily for 2 weeks, then three times a week for 22 weeks. Efficacy, safety, and cost-effectiveness were assessed. A Markov model was developed to investigate cost-effectiveness in patients with chronic hepatitis C treated by different IFN-based treatment strategies. Results. Of the 104 study patients, a sustained virological response (SVR) was achieved in 66 (63%). Logistic regression analysis revealed that genotype 2, lower hepatitis C virus RNA levels, and patient age were independently associated with SVR. The response rate was significantly higher in patients with genotype 2 (51/66, 77%) versus genotype 1 (15/38, 40%). Cost-effectiveness analysis in patients with genotype 2 revealed that high-dose induction with consensus IFN monotherapy was as highly cost-effective as pegylated IFN plus ribavirin. Conclusion. Consensus IFN monotherapy with high-dose induction shows high efficacy and cost-effectiveness in chronic hepatitis C patients with genotype 2 infection. Thus, it may be a reliable alternative in aged patients and for those excluded from standard combination therapy.

AB - Objective. Several treatment strategies for patients with chronic hepatitis C have been compared mainly in terms of their efficacy, and it has been found that pegylated interferon (IFN) plus ribavirin has become the standard therapy, but aged patients may not tolerate ribavirin and the cost-effectiveness of treatment should also be further considered. We conducted a study to evaluate the efficacy, safety, and cost-effectiveness of consensus IFN monotherapy with high-dose induction for patients with chronic hepatitis C in clinical practice. Material and Methods. We consecutively enrolled 104 patients with chronic hepatitis C. Patients were scheduled to receive 12 or 18 μg of consensus IFN daily for 2 weeks, then three times a week for 22 weeks. Efficacy, safety, and cost-effectiveness were assessed. A Markov model was developed to investigate cost-effectiveness in patients with chronic hepatitis C treated by different IFN-based treatment strategies. Results. Of the 104 study patients, a sustained virological response (SVR) was achieved in 66 (63%). Logistic regression analysis revealed that genotype 2, lower hepatitis C virus RNA levels, and patient age were independently associated with SVR. The response rate was significantly higher in patients with genotype 2 (51/66, 77%) versus genotype 1 (15/38, 40%). Cost-effectiveness analysis in patients with genotype 2 revealed that high-dose induction with consensus IFN monotherapy was as highly cost-effective as pegylated IFN plus ribavirin. Conclusion. Consensus IFN monotherapy with high-dose induction shows high efficacy and cost-effectiveness in chronic hepatitis C patients with genotype 2 infection. Thus, it may be a reliable alternative in aged patients and for those excluded from standard combination therapy.

KW - Chronic hepatitis C

KW - Consensus interferon

KW - Cost-effectiveness

KW - Genotype 2

KW - High-dose induction

UR - http://www.scopus.com/inward/record.url?scp=78651356512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651356512&partnerID=8YFLogxK

U2 - 10.3109/00365521.2010.516449

DO - 10.3109/00365521.2010.516449

M3 - Article

VL - 46

SP - 79

EP - 90

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 1

ER -